Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet
Key PointsEli Lilly’s next-gen anti-obesity medicine has posted highly encouraging clinical trial results.
Eli Lilly, the biggest player in the healthcare sector, has seen impressive returns on its investment in the anti-obesity market. Its lead product, Zepbound, has been a standout performer, boasting exceptional sales growth. However, the company has a number of promising pipeline drugs, one of which may surpass Zepbound in performance.
Zepbound's unique selling point is its dual action on GLP-1 and GIP gut hormones, a strategy that has yielded superior weight loss results compared to its main rival, Wegovy, which only stimulates GLP-1.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
